Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of REGN668 with topical corticosteroids in moderate-to-severe atopic dermatitis
2012-000946-37Phase 2Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Apr 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing SAR231893 + topical corticosteroids with Placebo + topical corticosteroids (2 arms). Primary endpoints: Incidence of adverse events and Severity of adverse events. Started Apr 2012; status: completed.
02
Drugs
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2012-000946-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000946-37.